Status and phase
Conditions
Treatments
About
A randomized, open-label, single dose, two-way crossover study to compare the pharmacokinetics and safety/tolerability of CKD-370 with D745 in healthy volunteers
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
History of clinically significant hepatic, renal, nervous, immune, respiratory, digestive, urinary, endocrine, hemato-oncology, cardiovascular systemic disease or psychosis disorder
Clinical laboratory test values are outside the accepted normal range at Screening
Current smokers or those who cannot quit smoking during the period from 90 days before the first IP dosing to the last discharge.
Subject who drink excessive caffeine or alcohol continuously and who cannot discontinue caffeine or alcohol intake during the period from 3 days before the first IP dosing to the last discharge.
Participated in a clinical trial within 90 days prior to first IP dosing
Not eligible to participate for the study at the discretion of Investigator
Other exclusive inclusion criteria, as defined in the protocol
Primary purpose
Allocation
Interventional model
Masking
28 participants in 2 patient groups
Loading...
Central trial contact
Deok Yong Yoon; Kyung Sang Yu, Ph.D. M.D.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal